未来,如何为用户提供更好的产品和服务成为众安的新命题。中国干细胞药物迎来新突破——近日,由铂生卓越生物科技(北京)有限公司(即“铂生生物”)自主研发的艾米迈托赛注射液(商品名:睿铂生)在北京大学人民医院开出首张处方,正式进入市场。作为国内首款获批的干细胞治疗药品,“睿铂生”单次治疗费用仅1.98万元,价格仅为半个月前美国FDA批准上市的同类适应症干细胞药品的1/70,用于治疗14岁以上消化道受累...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.